Table I. Pathway enrichment analysis with proteins downregulated in ERU.

p value	q value	Pathway	Source	Size	Overlap downregulated in ERU1	Overlap unchanged2 or upregulated3§
0.000	0.000	Akap95 role in mitosis and chromosome dynamics	BioCarta	13	DDX5*; H3F3A
0.000	0.000	Citrulline biosynthesis	HumanCyc	9	GLS; PRODH*
0.000	0.000	Amino acid transport across the plasma membrane	Reactome	29	SLC38A3; SLC3A2
0.000	0.000	RNA polymerase I Promoter clearance (includes “RNA Polymerase I promoter opening”)	Reactome	54	H3F3A; HIST1H2BJ; HIST1H4K
0.000	0.000	Notch signaling pathway	KEGG	47	CTBP2; KAT2A*
0.000	0.005	Cardiac muscle contraction	KEGG	79	ATP1A3; ATP1B1; COX4I1; COX5B; COX6B1; COX7A1*; COX7A2; COX7A2L*; MYH6; MYH7*; UQCR*; UQCRB	ATP1A1; ATP1B2; ATP2A2; COX5A; CYC1;TPM2*; UQCRC1; UQCRC2; UQCRH;
0.001	0.013	Visual signal transduction	BioCarta	14	GNAT1; GRK1*; SLC25A18*; SLC25A22*	GNB1
0.001	0.012	Visual signal transduction: Rods	PID	25	GNAT1; GRK1*; RDH12; SAG	GNB1
0.004	0.044	Visual signal transduction: Cones	PID	24	ARR3*; GRK1*; RDH12	GNB1
0.004	0.037	Transcription (includes “RNA polymerase I transcription”)	Reactome	175	H3F3A; HIST1H2BJ; HIST1H4K	PTRF§*
0.004	0.025	Formation and maturation of mRNA transcript (includes “elongation and processing of capped transcripts”; “mRNA splicing”; “viral messenger RNA synthesis”; “processing of capped intron-containing pre-mRNA”)	Reactome	167	HNRNPC*; HNRNPK; HNRNPM*; PCBP1; PCBP2	HNRPU*; HNRPR*; HNRPD*
0.009	0.057	Electron transport chain	Reactome	76	COX4I1; COX5B; COX6B1; COX7A2L*; NDUFA4*; NDUFA9; NDUFB1*; NDUFB10; NDUFB11; NDUFB4; NDUFB5*; NDUFB8*; NDUFS2; UQCR*; UQCRB	CYCS*; CYC1; COX5A; ETFB*; NDUFS1; NDUFS3; NDUFS5*; NDUFS7*; NDUFAB1*; NDUFA6*; NDUFS8; NDUFA13; NDUFV1*; NDUFV2*; NDUFB9*; NDUFA10; SDHC; UQCRC1; UQCRC2; UQCRH;

¹ p < 0.05 and more than 2-fold upregulated.

² p > 0.05 or less than 2-fold upregulated.

³ p < 0.05 and more than 0.5-fold downregulated in ERU.

* Identified and quantified by only one peptide.